SyBridge Technologies Completes Acquisition Of Active Industrial Solutions, Inc. And Active Industrial Solutions Tennessee

February 19, 2021

SyBridge Technologies notes this transaction marks the further expansion by SyBridge in the mobility tooling industry, especially in the fast-growing lighting, fascia, and grille segment.

New York-based private equity firm Crestview Partners established SyBridge in 2019 and committed $200 million of equity to create a market leader spanning across end-markets, geographies, and advanced technological capabilities to provide value-added solutions to its customers.

The combination of AIS and Concours will create the largest tooling and mold solutions provider in North America. In additional to greater economy of scale, this acquisition will also expand Concours’ capabilities in highly complex precision tooling solutions for lighting applications.

Headquartered in Windsor, Ontario, AIS is a leader in engineering, manufacturing and servicing complex plastic injection molds and lighting reflex components for the mobility industry. Founded in 1977, AIS has grown from a mold maker to a tooling solutions provider through continuously investing in the latest technologies and a strong commitment to lean manufacturing.

“AIS has been a strong player with an excellent reputation in quality and operations. Taking the best from both companies, we will create a transformative company to better meet customer needs in today’s global tooling industry,” said Andy Aiton, President of Concours. “The combined company will have a strong footprint across Canada, U.S., Mexico and Asia. This is a major step in our effort to build unmatched ability to take on large global tooling programs in the future.”

Tony Nardone, CEO of SyBridge, added, “This transaction also includes a dedicated service facility in Southern U.S., which gives us a total of four customer service centers in North America. As we look to the future, service and technology are key drivers of our growth strategy.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version